Back

Laudanosine restricts Ebola virus entry by targeting TPC2-dependent endolysosomal trafficking

Seitz, T.; Koengeter, J.; Klute, S.; Kraft, F.; Clesle, D. C.; Tschampel, L.; Preising, N.; Rodriguez Alfonso, A. A.; Wiese, S.; Ständker, L.; Jung, C.; Jacob, T.; Köhler, J.; Weidinger, G.; Biedenkopf, N.; Sparrer, K. M. J.; Kirchhoff, F.; Zech, F.

2026-06-18 microbiology
10.64898/2026.06.17.732874 bioRxiv
Show abstract

Late endosome-dependent viruses, including filo- and arenaviruses, rely on host endolysosomal trafficking for productive infection. Here, we used a dual-colour Vesicular stomatitis virus (VSV) based pseudoparticle screen of CytoSorb-derived fractions to identify inhibitors of the Zaire Ebolavirus glycoprotein (GP)-mediated entry. Iterative chromatographic purification and mass spectrometry identified Laudanosine, a degradation product of the clinically used neuromuscular blocker Atracurium, as the antiviral compound. Laudanosine specifically inhibited entry mediated by Ebola, Marburg, Lymphocytic choriomeningitis and Lassa virus glycoproteins without affecting VSV-G-dependent entry. Importantly, Laudanosine inhibited authentic Ebola virus infection without detectable cytotoxicity in cell culture and embryonic zebrafish. Molecular dynamics simulations suggest stable association of Laudanosine with the allosteric inhibitory pocket of the lysosomal two-pore channel (TPC2). Consistently, Laudanosine impairs autophagic flux and disrupts endolysosomal trafficking. Together, our findings identify Laudanosine as a previously unrecognised inhibitor of TPC2-dependent entry of highly lethal viral pathogens.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.